Nektar Therapeutics (NKTR) Lost Less than Expected in Q2
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $67.10 -1.84%
Revenue Growth %: -11.4%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -11.4%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.26), $0.11 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $28.5 million versus the consensus estimate of $19.76 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- UBS cuts KOSPI target by nearly 10% to reflect higher rates
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
